Journal Article DKFZ-2025-01956

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Oleandrin-mediated suppression of MELK induces apoptosis, autophagy, and ferroptosis in human non-small cell lung cancer cells.

 ;  ;  ;  ;  ;  ;  ;

2025
Elsevier Mùˆnchen [u.a.]

Phytomedicine 147, 157173 () [10.1016/j.phymed.2025.157173]
 GO

Abstract: Non-small-cell lung cancer NSCLC is the major diagnosed type of lung cancers in the USA and Europe. It is generally related to poor prognosis and low rates of survival. Oleandrin is a cardiac glycoside occurring naturally in Nerium oleander (Apocynaceae).To explore the potential therapeutic value of oleandrin against different cancer types with emphasis on NSCLC.The effect of oleandrin in inhibiting the growth of different cancer cells was measured. In addition, oleandrin activity in inhibiting cell migration, suppression of MELK and inducing different modes of cell deaths were investigated using in silico, in vitro, and in vivo methods.Oleandrin showed activity at low nanomolar level against 17 different types of cancer cells including NSCLC. Our investigations in A549 cells indicated that oleandrin is a MELK inhibitor, as it disrupted the microtubule network and inhibited migration of A549 cells. Moreover, it induced apoptosis, autophagy, and ferroptosis. Furthermore, our in vivo data revealed that oleandrin had significantly decreased tumor growth in a A549 xenograft zebrafish model in a dose-dependent manner. In silico analyses revealed that oleandrin bound to the ligand binding pocket with higher binding affinity than the known inhibitor MELK-8a. The binding was further confirmed in vitro using microscale thermophoresis. An ADMET (absorption, distribution, metabolism, excretion, toxicity) analysis, together with our in vivo toxicity studies and the previous clinical studies suggest that oleandrin has an acceptable safety profile.Oleandrin could potentially have therapeutic effects for NSCLC patients and possibly for other cancer types.

Keyword(s): Humans (MeSH) ; Cardenolides: pharmacology (MeSH) ; Carcinoma, Non-Small-Cell Lung: drug therapy (MeSH) ; Animals (MeSH) ; Apoptosis: drug effects (MeSH) ; Zebrafish (MeSH) ; Lung Neoplasms: drug therapy (MeSH) ; Autophagy: drug effects (MeSH) ; Ferroptosis: drug effects (MeSH) ; A549 Cells (MeSH) ; Cell Movement: drug effects (MeSH) ; Cell Line, Tumor (MeSH) ; Antineoplastic Agents, Phytogenic: pharmacology (MeSH) ; Xenograft Model Antitumor Assays (MeSH) ; Nerium: chemistry (MeSH) ; Cardiac glycosides ; In vivo ; NSCLC ; Natural products ; Nerium oleander ; Phytotherapy ; Programmed cell death ; Cardenolides ; oleandrin ; Antineoplastic Agents, Phytogenic

Classification:

Contributing Institute(s):
  1. B063 Krebsgenomforschung (B063)
Research Program(s):
  1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2025
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2025-09-25, last modified 2025-09-26



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)